Etanidazole

Title: Etanidazole
CAS Registry Number: 22668-01-5
CAS Name: N-(2-Hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide
Manufacturers' Codes: DUP-453; NSC-301467; SR-2508
Trademarks: Radinyl (Roberts)
Molecular Formula: C7H10N4O4
Molecular Weight: 214.18
Percent Composition: C 39.25%, H 4.71%, N 26.16%, O 29.88%
Literature References: Oxygen-mimetic which renders hypoxic cells sensitive to chemo- and radiotherapy. Prepn: A. G. Beaman et al., Antimicrob. Agents Chemother. 1967, 520. See also: W. W. Lee et al., US 4371540 (1983 to U.S. Sec'y Health Human Serv.). Pharmacology: J. M. Brown et al., Int. J. Radiat. Oncol. Biol. Phys. 7, 695 (1981). HPLC determn in biological materials: R. Ward, P. Workman, J. Chromatogr. 420, 223 (1987). Clinical pharmacokinetics and efficacy in radiation therapy: T. H. Wasserman et al., Radiother. Oncol. 20, Suppl. 1, 129 (1991). Evaluation in combination with alkylating agents: L. N. Shulman et al., Int. J. Radiat. Oncol. Biol. Phys. 29, 545 (1994).
Properties: Crystals from ethanol, mp 162-163° (Beaman); also reported as white powder from ethyl acetate + methanol, mp 164.5-165° (Lee). Partition coefficient (octanol/water): 0.046. uv max (isopropanol): 313 nm (e 7800). Soly in isotonic saline: 200 mg/ml.
Melting point: mp 162-163° (Beaman); mp 164.5-165° (Lee)
Log P: Partition coefficient (octanol/water): 0.046
Absorption maximum: uv max (isopropanol): 313 nm (e 7800)
Therap-Cat: Antineoplastic adjunct (radiosensitizer).
Keywords: Antineoplastic Adjunct; Radiosensitizer.
Etaqualone eta-Tocopherol Eterobarb Etersalate Ethacrynic Acid

Etanidazole
Etanidazole.svg
Identifiers
CAS number 22668-01-5 N
PubChem 3276
ChemSpider 3161 YesY
ChEMBL CHEMBL47405 YesY
Jmol-3D images Image 1
Properties
Molecular formula C7H10N4O4
Molar mass 214.18 g mol−1
 N (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Etanidazole is a nitroimidazole drug used for its radiosensitizing properties. Administration of etanidazole results in a decrease of glutathione concentration and inhibits glutathione S-transferase.[1] The result is that tissues become more sensitive to the ionizing radiation used in cancer treatment.